MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12072-016-9726-5

Медицинская библиотека · Hepatology international · 2016

A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.

Lim Young-Suk, Ahn Sang Hoon, Lee Kwan Sik, Paik Seung Woon, Lee Youn-Jae, Jeong Sook-Hyang, Kim Ju-Hyun, Yoon Seung Kew, Yim Hyung Joon, Tak Won Young, Han Sang-Young, Yang Jenny C, Mo Hongmei, Garrison Kimberly L, Gao Bing, Knox Steven J, Pang Phillip S, Kim Yoon Jun, Byun Kwan-Soo, Kim Young Seok, Heo Jeong, Han Kwang-Hyub

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

The standard-of-care regimen for chronic hepatitis C virus (HCV) infection in Korea, pegylated-interferon-alpha plus ribavirin, is poorly tolerated. Ledipasvir/sofosbuvir is a two-drug, fixed-dose combination tablet approved in the USA, European Union, and Japan for chronic genotype 1 HCV infection.

METHODS

This single-arm, phase IIIb study (NCT02021656) investigated the efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination tablet for 12 weeks in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 HCV with or without compensated cirrhosis.

RESULTS

The proportion of patients with sustained virologic response 12 weeks after treatment discontinuation (SVR12) was 99 % (92/93), with rates of 100 % (46/46) and 98 % (46/47) in treatment-naïve and treatment-experienced patients, respectively. There were no on-treatment failures. One patient relapsed after the end of treatment. The most common treatment-emergent adverse events were headache (8 %, 7/93) and fatigue (6 %, 6/93). There were no grade 3 or 4 adverse events, seven grade 3 laboratory abnormalities, and one premature discontinuation of study treatment (due to nonserious mouth ulceration). None of the three reported serious adverse events were related to treatment.

CONCLUSIONS

These data suggest that 12 weeks of ledipasvir/sofosbuvir is effective and well tolerated in treatment-naïve and treatment-experienced Korean patients with chronic genotype 1 HCV infection.

Для цитирования: Lim Young-Suk, Ahn Sang Hoon, Lee Kwan Sik, Paik Seung Woon, Lee Youn-Jae, Jeong Sook-Hyang, Kim Ju-Hyun, Yoon Seung Kew, Yim Hyung Joon, Tak Won Young, Han Sang-Young, Yang Jenny C, Mo Hongmei, Garrison Kimberly L, Gao Bing, Knox Steven J, Pang Phillip S, Kim Yoon Jun, Byun Kwan-Soo, Kim Young Seok, Heo Jeong, Han Kwang-Hyub. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.. Hepatology international. 2016. DOI: 10.1007/s12072-016-9726-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.